New study shows promising results for allograft from Regenative
Labs
PENSACOLA, Fla., July 31,
2024 /PRNewswire/ -- More than 350,000 hip
replacements are performed in the U.S. each year. Typically,
patients in need of hip cartilage repairs seek minimally invasive
options first, making Wharton's jelly a promising alternative for
musculoskeletal defects.
A recent study, titled Retrospective Evaluation of
Cryopreserved Human Umbilical Cord Tissue Allografts in the
Supplementation of Cartilage Defects Associated with Hip
Osteoarthritis, showed that patients reported less pain and
stiffness when receiving an application of a Wharton's Jelly
allograft from Regenative Labs. The overall objective of this study
was to evaluate the improvement of patient-reported pain, quality
of life, and functionality scales after applying Wharton's jelly in
hip defects.
Dr. Albert Lai of Desert Pain
Specialists and Centers of Rehabilitation and Pain Medicine in
California and Dr. Conrad Tamea of Orthopedic Associates of
Tampa Bay participated in the
study. A double board-certified physician with specialties in
physical medicine rehabilitation and pain medicine, Dr. Lai said
the Wharton's jelly therapy was providing relief for their
patients.
"Incorporating Wharton's jelly into our practice has provided an
effective conservative option for patients with hip defects that
outperforms conventional therapies," said Dr. Lai. "Using the
structural connective tissue allografts has allowed many patients
to avoid surgery altogether and significantly improve their quality
of life."
The study follows 69 patients with hip defects from 26 private
practices who received an application of a Wharton's jelly
allograft from Regenative Labs. Prior to the study, these patients
had failed at least 8 weeks of conservative treatment.
Patient outcomes were tracked on a 90-day calendar using three
scales including the Numeric Pain Rating Scale (NPRS), Quality of
Life Scales (QOLS), and the Western
Ontario and McMaster University
Arthritis Index (WOMAC) covering pain, stiffness, and
functionality. There were statistically significant differences
between the initial application and day 90 for the NPRS and WOMAC
scales.
The application of Wharton's jelly allografts in this
retrospective cohort was observed to promote decreases in
patient-reported NPRS scores, pain and stiffness and to improve
function. These improvements were consistent across age groups but
were most notable for the elderly, who generally have a slower and
less effective recovery rate after conservative treatment and
surgical procedures.
Because of the success shown by NPRS and WOMAC in decreasing
pain in the elderly population, Regenative Labs CEO Tyler Barrett said more studies are warranted to
evaluate the safety and efficacy of Wharton's Jelly, specifically
in patients older than 65.
"Total hip replacements by Medicare alone are estimated to make
up somewhere between $7 billion to
$10 billion in annual healthcare
expenditures in the U.S. It's clear that the need for this type of
research is necessary and quite frankly overdue," said Barrett.
The positive results from this study and the current literature
provide a foundation to study applications of Wharton's Jelly in
other musculoskeletal injuries to ultimately improve the quality of
life and reduce the economic burden of multiple conservative
treatments or surgical procedures. Dr. Tamea said Wharton's jelly
allografts have reduced pain and stiffness for his patients — and
in some cases — reduced the need for surgery.
"As a board-certified Orthopedic Surgeon with more than 25 years
of operative experience, I can say after using Wharton's jelly
allografts in more than 200 cases, I have found them to be
extremely beneficial to my patients," said Dr. Tamea. "Orthopedic
applications using Wharton's jelly — including in the knee,
shoulder, hip, and spine — are more often than not preventing the
need for surgery that results in a prolonged recovery time, lost
wages and great financial cost."
Barrett and the Regenative Labs' team hope to enlist physicians
to take part in studies regarding uncovered uses. Physicians will
have their outcomes highlighted, furthering the understanding of
regenerative medicine and uncovering new applications for this
groundbreaking field.
Physicians can contact Regenative Labs to get their
practice involved today.
Read the full study here.
Wharton's jelly explained:
https://www.youtube.com/watch?v=oeLt-SKpsnc
About Regenative Labs
Regenative Labs produces
regenerative medicine products to address the root cause of a
patient's debilitating situation using Wharton's Jelly innovations
rather than masking the pain with other treatments. Regenative Labs
works closely with scientists, physicians, hospitals, and surgery
centers to constantly monitor and improve patient progress and
outcomes for new product development. Formed by veteran industry
professionals familiar with the daily challenges of innovations in
healthcare, the company provides effective and minimally invasive
options for patients. Regenative Labs' expert product research and
development team complies with FDA guidelines of minimal
manipulation for homologous use. The company adheres to AATB and
FDA guidelines. Learn more at www.regenativelabs.com
About Dr. Albert Lai
A
southern Californian native, Dr. Lai completed his medical training
at Tufts University, where he
subsequently served as a clinical instructor. He is board certified
in Physical Medicine and Rehabilitation. He also holds board
certifications in Pain Medicine and Independent Medical Examiners.
Dr. Lai has served as the managing partner at the offices of Desert
Pain & Rehabilitation Associates based in Rancho Mirage for the past 18 years and as
medical director of Centers of Rehabilitation and Pain Medicine in
Placentia, California. Learn more
at the Centers of Rehabilitation website: Pain Clinic Orange County
| Professional Pain Management in OC (ocpain.net)
About Dr. Conrad
Tamea
Dr. Tamea is a board-certified Orthopedic
Surgeon, who now focuses solely on regenerative medicine. He
received his education from the College of
William and Mary, Drexel
University, Hahnemann Medical University, and the
University of Kansas Orthopedic
Residency Program. Dr. Tamea utilizes his knowledge and experience
from over three decades as a surgeon and over a decade of
regenerative medicine and combines this knowledge with
state-of-the-art equipment at his clinic at Orthopedic Associates
of Tampa Bay.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/is-whartons-jelly-the-new-gold-standard-for-hip-cartilage-repair-302210465.html
SOURCE Regenative Labs